COSTA MESA, Calif.,/IReach-PRNewswire/– WCCT Global, a full-service contract research organization, is announcing the opening of an office and clinical operations in Seoul, Korea. With the expansion of operations into South Korea, the company is poised to further establish itself as a global CRO. The expansion is a part of the company’s efforts to increase its capacity for conducting high quality clinical research in one of Asia’s fastest-growing countries for biopharmaceutical development. In addition to managing research initiatives in South Korea, WCCT will also be host to educational events designed for investigators, as well as local and multi-national biopharmaceutical companies and other parties, interested in learning about participation in clinical research on a global scale. Additionally, WCCT plans to leverage its early clinical development expertise in collaboration with key academic institutions throughout the country.

“By establishing offices in South Korea, we will expand our clinical research expertise capabilities and build a support infrastructure in Korea. We believe our experience and expertise can help the Korean clinical CRO market expand its scope of services,” said WCCT Global Chairman and CEO, Dr. Kenneth Kim. The company also intends to help broaden the scope of services offered across the Pan-Pacific region. The new office will serve as the strategic base for WCCT’s expansion into Asia and will allow the company to conduct trials throughout the Pan-Pacific area and reach special patient populations within South Korea.

WCCT’s Director of Corporate Development in Korea, Jaeho Lee, stated:  “By opening an office in South Korea, we can further enhance our corporate goal to manage global clinical trials. Currently, WCCT is known as the leader in conducting ethnic sensitivity and Ethnobridging trials within the United States and will use this new global perspective to improve the way it conducts research in the Korean population. By broadening our in-country knowledge of Korea, we believe we will be able to increase our competitive position in the Pan-Pacific region. This move marks a huge transition for how the WCCT can make a greater impact on medical research outside of the United States.”

Safe Harbor Statement

Statements about WCCT Global’s future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. WCCT Global intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting WCCT Global’s operations, markets and profitability, actual results could differ materially and adversely from the expected results.